A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
Status:
COMPLETED
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male subjects on their pharmacokinetics, safety and tolerability